Abatacept-Associated behavioral, inflammatory, and immunohistochemical changes in a rotenone-induced rat model of parkinsonism
Abstract
Background Neuroinflammation and peripheral immune dysregulation are implicated in Parkinson’s disease, supporting evaluation of immunomodulatory interventions. We investigated outcomes associated with abatacept administered before rotenone exposure, alone or combined with L-DOPA/benserazide administered concurrently with rotenone, in a rat model of parkinsonism. Methods and results Thirty male Wistar rats were randomly assigned to five groups: control, rotenone, rotenone plus abatacept, rotenone plus L-DOPA/benserazide, and combined treatment. Rotenone and L-DOPA/benserazide were administered concurrently for 14 days; abatacept was administered twice, beginning 48 h before rotenone. Motor performance and serum IL-10 and TNF-α were assessed. TH and pSer129 α-synuclein immunopositivity in the substantia nigra and pSer129 α-synuclein and TNF-α immunopositivity in peripheral tissues were evaluated semi-quantitatively. Compared with rotenone, abatacept increased rearing, ambulation, and serum IL-10 and decreased serum TNF-α, without significantly altering rotarod performance or nigral immunopositivity. L-DOPA improved all motor measures and increased serum IL-10 but did not significantly alter serum TNF-α or nigral immunopositivity. Combined treatment improved all motor measures, increased serum IL-10 and nigral TH immunopositivity, decreased serum TNF-α, and reduced pSer129 α-synuclein immunopositivity in four peripheral tissues and TNF-α immunopositivity in the liver and jejunum. Serum TNF-α was lower with abatacept than with L-DOPA. Compared with L-DOPA, combined treatment additionally affected only ambulation and serum TNF-α. Conclusions Abatacept was associated with selected motor and cytokine changes in experimental parkinsonism. Combined treatment showed a broader pattern of changes relative to rotenone, but its advantages over L-DOPA were outcome-specific. Peripheral pSer129 α-synuclein findings represent exploratory changes in immunoreactivity rather than evidence of altered α-synuclein aggregation. These findings, obtained under a pretreatment/concurrent administration design, support further investigation but do not establish therapeutic efficacy after parkinsonian pathology has developed, a generalized combination benefit, or an underlying immune mechanism.